1 November 2018

Recently, Alfredo Cabrera-Orefice, Ulrich Brandt and colleagues, theme Mitochondrial Diseases, concluded in Nature Communications that the movement of a critical loop of subunit ND3 located at the ubiquinone-binding pocket of respiratory complex I is required to drive proton pumping. These results corroborate one of the central predictions of their model for the mechanism of energy conversion by this mitochondrial enzyme.

Publication in Nature Communications: link.

Respiratory complex I feeds redox equivalents into oxidative phosphorylation. By linking electron transfer from NADH to ubiquinone with the translocation of protons across the inner mitochondrial membrane, it generates a major portion of the proton-motive force driving aerobic ATP synthesis, protein import and the transport of metabolites. Complex I is also a key player in signaling and pathologic mechanisms associated with reactive oxygen species (ROS) in humans. Yet, the molecular mechanism and regulation of energy conversion and ROS production by complex I remain poorly understood. However, they have hypothesized that during energy conversion by complex I, electron transfer onto ubiquinone triggers the concerted rearrangement of three protein loops of subunits ND1, ND3 and 49-kDa, thereby generating the power-stroke driving proton pumping. Their results show that fixing loop TMH1-2 of subunit ND3 to the nearby subunit PSST via a disulfide bridge introduced by site-directed mutagenesis reversibly disengages proton pumping without impairing ubiquinone reduction, inhibitor binding or the Active/Deactive transition. The X-ray structure of this variant of complex I indicates that the cross-link immobilizes but does not displace the tip of loop TMH1-2. Authors conclude that movement of this critical loop is required to drive proton pumping, which corroborates one of the central predictions of their model for the mechanism of energy conversion by complex I. Being now able to disconnect selectively and reversibly the proton pumping machinery from the redox chemistry of ubiquinone and its control by the A/D transition in itself provides an invaluable tool to finally elucidate the mechanism and regulation of mitochondrial complex I.

Related news items

Hans Spelbrink is beneficiary of the MITGEST Doctoral Network which receives 2.6 million euros funding (PhD positions available)

27 September 2022

EU has granted the new Doctoral Network “MITGEST” (Quality Control of the Mitochondrial Gene Expression System in Health and Disease), of which Radboudumc is one of the partners, with 2.6 million euros of funding under the Marie Sklodowska-Curie Actions.

read more

Khondrion begins study on optimal dosage of new drug

10 February 2020 Pharmaceutical company Khondrion, a spin-off from Radboudumc, has taken another important step in the development of its drug sonlicromanol. The first patients have used the drug as part of a phase 2b study, which focuses on determining the optimum dose and efficacy. read more

Stofwisselkracht grant for Daan Panneman and Richard Rodenburg

16 January 2020 Daan Panneman & Richard Rodenburg have been awarded a Stofwisselkracht grant for their proposal “CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients”. Together with Omar Tutakhel & Jan Smeitink they will investigate the possibility of using CRISPR/Cas9 knock-in. read more

New mitochondrial DNA maintenance disease uncovered

1 October 2019 The group of Hans Spelbrink, theme Mitochondrial diseases, and colleagues, has identified and characterized mutations in the mtDNA maintenance gene SSBP1 in families with optic atrophy and foveopathy. This paper is now online in The Journal of Clinical Investigation. read more

Mitochondrial DNA replication factors in mtRNA metabolism

5 February 2019 Hans Spelbrink, theme Mitochondrial diseases, published in Nucleic Acids Research, that two factors in mitochondrial DNA replication, namely the mtDNA helicase Twinkle and the mtDNA single-stranded DNA-binding protein mtSSB, play an important role in mitochondrial RNA metabolism. read more

Biodegradable nanoreactors demonstrate ROS shielding in human-complex-I-deficient fibroblasts

9 July 2018 Researchers of the Radboudumc and colleagues have successfully developed enzyme-loaded polymersomal nanoreactors capable of undergoing cellular integration in a controlled fashion and, subsequently, function as synthetic organelles. read more